Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration

Scott,Katherine A.; Dalgleish,Angus G.; Liu,Wai M.

doi:10.3892/ijo.2017.4022

Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration

Authors:
- Katherine A. Scott
- Angus G. Dalgleish
- Wai M. Liu
View Affiliations

Affiliations: Department of Oncology, Institute for Infection and Immunity, St George's, University of London, London SW17 0RE, UK
Published online on: May 29, 2017 https://doi.org/10.3892/ijo.2017.4022
Pages: 369-377

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phytocannabinoids possess anticancer activity when used alone, and a number have also been shown to combine favourably with each other in vitro in leukaemia cells to generate improved activity. We have investigated the effect of pairing cannabinoids and assessed their anticancer activity in cell line models. Those most effective were then used with the common anti-leukaemia drugs cytarabine and vincristine, and the effects of this combination therapy on cell death studied in vitro. Results show a number of cannabinoids could be paired together to generate an effect superior to that achieved if the components were used individually. For example, in HL60 cells, the IC50 values at 48 h for cannabidiol (CBD) and tetrahydrocannabinol (THC) when used alone were 8 and 13 µM, respectively; however, if used together, it was 4 µM. Median-effect analysis confirmed the benefit of using cannabinoids in pairs, with calculated combination indices being <1 in a number of cases. The most efficacious cannabinoid-pairs subsequently synergised further when combined with the chemotherapy agents, and were also able to sensitise leukaemia cells to their cytotoxic effects. The sequence of administration of these drugs was important though; using cannabinoids after chemotherapy resulted in greater induction of apoptosis, whilst this was the opposite when the schedule of administration was reversed. Our results suggest that when certain cannabinoids are paired together, the resulting product can be combined synergistically with common anti-leukaemia drugs allowing the dose of the cytotoxic agents to be dramatically reduced yet still remain efficacious. Nevertheless, the sequence of drug administration is crucial to the success of these triple combinations and should be considered when planning such treatments.

View Figures

View References

1	Mechoulam R, Hanuš LO, Pertwee R and Howlett AC: Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 15:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pacher P, Bátkai S and Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58:389–462. 2006. View Article : Google Scholar : PubMed/NCBI
3	Munson AE, Harris LS, Friedman MA, Dewey WL and Carchman RA: Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 55:597–602. 1975. View Article : Google Scholar : PubMed/NCBI
4	Guzmán M: Cannabinoids: Potential anticancer agents. Nat Rev Cancer. 3:745–755. 2003. View Article : Google Scholar : PubMed/NCBI
5	Fowler CJ: Delta(9)-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clin Pharmacol Ther. 97:587–596. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ladin DA, Soliman E, Griffin L and Van Dross R: Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Front Pharmacol. 7:3612016. View Article : Google Scholar : PubMed/NCBI
7	Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M and Velasco G: A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 10:90–103. 2011. View Article : Google Scholar : PubMed/NCBI
8	Scott KA, Dalgleish AG and Liu WM: The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 13:2955–2967. 2014. View Article : Google Scholar : PubMed/NCBI
9	Basu S and Dittel BN: Unraveling the complexities of canna-binoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res. 51:26–38. 2011. View Article : Google Scholar : PubMed/NCBI
10	Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M and Guzmán M: Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 6:313–319. 2000. View Article : Google Scholar : PubMed/NCBI
11	Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C, Torres S, García S, et al: Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 119:1359–1372. 2009. View Article : Google Scholar : PubMed/NCBI
12	Velasco G, Sánchez C and Guzmán M: Anticancer mechanisms of cannabinoids. Curr Oncol. 23:S23–S32. 2016.PubMed/NCBI
13	Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T and Liu WM: Cannabis-induced cytotoxicity in leukemic cell lines: The role of the cannabinoid receptors and the MAPK pathway. Blood. 105:1214–1221. 2005. View Article : Google Scholar
14	Scott KA, Shah S, Dalgleish AG and Liu WM: Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Anticancer Res. 33:4373–4380. 2013.PubMed/NCBI
15	Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P and Izzo AA: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 35:2787–2797. 2014. View Article : Google Scholar : PubMed/NCBI
16	Fraguas-Sánchez AI, Fernández-Carballido A and Torres-Suárez AI: Phyto-, endo- and synthetic cannabinoids: Promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. Expert Opin Investig Drugs. 25:1311–1323. 2016. View Article : Google Scholar : PubMed/NCBI
17	Liu WM, Gravett AM and Dalgleish AG: The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer. 128:1471–1480. 2011. View Article : Google Scholar
18	Liu WM, Scott KA, Shamash J, Joel S and Powles TB: Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma. 49:1800–1809. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
20	Van Dross R, Soliman E, Jha S, Johnson T and Mukhopadhyay S: Receptor-dependent and receptor-independent endocannabinoid signaling: A therapeutic target for regulation of cancer growth. Life Sci. 92:463–466. 2013. View Article : Google Scholar
21	Rocha FC, Dos Santos Júnior JG, Stefano SC and da Silveira DX: Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. 116:11–24. 2014. View Article : Google Scholar
22	Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M and Nagarkatti PS: Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res. 4:549–562. 2006. View Article : Google Scholar : PubMed/NCBI
23	McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS and Nagarkatti M: Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 70:897–908. 2006. View Article : Google Scholar : PubMed/NCBI
24	Liu WM: Enhancing the cytotoxic activity of novel targeted therapies - is there a role for a combinatorial approach? Curr Clin Pharmacol. 3:108–117. 2008. View Article : Google Scholar : PubMed/NCBI
25	De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P and Di Marzo V: Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 168:79–102. 2013. View Article : Google Scholar :
26	Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, et al: In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol. 23:S15–S22. 2016.PubMed/NCBI
27	Scott KA, Dennis JL, Dalgleish AG and Liu WM: Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Res. 35:5827–5837. 2015.PubMed/NCBI
28	Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar
29	Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH and Wilcken N: Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 12:CD0087922013.
30	Bonner JA and Kozelsky TF: The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol. 39:109–112. 1996. View Article : Google Scholar : PubMed/NCBI
31	Billard C: BH3 mimetics: Status of the field and new developments. Mol Cancer Ther. 12:1691–1700. 2013. View Article : Google Scholar : PubMed/NCBI
32	Shapiro GI and Harper JW: Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest. 104:1645–1653. 1999. View Article : Google Scholar : PubMed/NCBI
33	Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
34	Caffarel MM, Moreno-Bueno G, Cerutti C, Palacios J, Guzman M, Mechta-Grigoriou F and Sanchez C: JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 27:5033–5044. 2008. View Article : Google Scholar : PubMed/NCBI